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Background: The careHPV assay is a test for high-risk (HR) human papillomaviruses (HPV) detection designed to be affordable in
resource-poor settings. We evaluated the performance of careHPV screening among 1052 women living with HIV/AIDS included in
the HARP (HPV in Africa Research Partnership) study in Burkina Faso (BF) and South Africa (SA).
Methods: Cervical samples were tested for HR-HPV by the careHPV and the INNO-LiPA HPV genotyping Extra assays. All women had
Pap smear testing, visual inspection with acetic acid/Lugol’s iodine (VIA/VILI) and colposcopy. Cervical biopsies were obtained for
participants who were HR-HPV DNA positive by careHPV or who had abnormalities detected on cytology, VIA/VILI or colposcopy.
Results: Overall, 45.1% of women had a positive careHPV test (46.5% in BF, 43.8% in SA). The careHPV positivity rate increased
with the grade of cytological lesions. Sensitivity and specificity of careHPV for the diagnosis of CIN2þ (n¼ 60, both countries
combined) were 93.3% (95% confidence interval (CI): 83.8–98.2) and 57.9% (95% CI: 54.5–61.2), respectively. Specificity increased
with CD4 count. careHPV had a similar clinical sensitivity but higher specificity than the INNO-LiPA assay for detection of CIN2þ .
Conclusions: Our results suggest that careHPV testing is a reliable tool for cervical cancer screening in HIV-1-infected women in
sub-Saharan Africa.
Cervical cancer, which is the fourth most common cancer in
women worldwide (Ferlay et al, 2015), is the most frequent cancer
and the leading cause of cancer death in Sub-Saharan African
women (Denny and Anorlu, 2012). Infection with human
immunodeficiency virus type 1 (HIV-1) is an additional risk
factor for the development of precancerous and cancerous cervical
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lesions (De Vuyst et al, 2008). Therefore, there is a need
for developing preventive measures in this highly exposed
population of African women living with HIV/AIDS (WLHA).
Unfortunately, cervical cancer screening programs are lacking in
most Sub-Saharan African countries and the diagnosis of cervical
cancer is generally made at an advanced stage of the disease when
treatment is unavailable or ineffective.
The development of precancerous cervical lesions that may
evolve to invasive carcinoma is associated with persistent cervical
infection with carcinogenic types of human papillomaviruses
(HPV) designated as high-risk (HR) HPV. It has been shown that
detection of HR-HPV in cervical samples is a highly sensitive tool
for identifying women at risk of precancerous or cancerous cervical
lesions (Cuzick et al, 2008; Ronco et al, 2014), but evaluation
among WLHA have only rarely been conducted.
The careHPV assay (Qiagen Corporation, Gaithersburg, MD,
USA) is a qualitative test for HR-HPV detection targeting 14 HR-
HPV types: HPV16, HPV18, HPV31, HPV33, HPV35, HPV39,
HPV45, HPV51, HPV52, HPV56, HPV58, HPV59, HPV66 and
HPV68. This microplate assay, based on the hybridisation of HR-
HPV DNA with a cocktail of RNA probes and chemiluminescence
signal amplification, was adapted from the Hybrid Capture
2 (HC2) assay (Qiagen) and designed to be simpler, more rapid
to use, and more affordable than HC2 in resource-poor settings
(Qiao et al, 2008; Gage et al, 2012).
HARP (HPV in Africa Research Partnership) is a research
programme conducted among WLHA in Burkina Faso (BF) and
South Africa (SA) with the aim to prospectively evaluate several
screening approaches for prevention of cervical cancer. In the first
round of screening, we have shown that, compared with the
INNO-LiPA HPV genotyping Extra assay, HC2 performed well in
this population, with a similar sensitivity and a higher specificity
for the diagnosis of high-grade cervical intraepithelial neoplasia
(CIN) grade 2 or more severe (CIN2þ ). We have already reported
an excellent agreement between HC2 and careHPV in a subgroup
of HARP participants (Ngou et al, 2013), comparable to what was
found in HIV-seronegative women in China (Chen et al, 2014; Lin
et al, 2014). However, it remained to be demonstrated that
careHPV had a good performance among African WLHA. For this
reason, we used the second round of screening in HARP 18
months after enrolment to evaluate the performance of careHPV
for the detection of CIN2þ .
MATERIALS AND METHODS
Study population. Participants were confirmed HIV-1 seropo-
sitive women aged 25–50 years recruited from the HIV outpatient
clinic of the University Hospital of Ouagadougou, BF, and HIV
treatment centres and surrounding primary health care clinics in
Hillbrow, Johannesburg, SA. Eligible women were invited for
inclusion in the study if they were resident in the recruitment city,
did not had a total hysterectomy or history of cervical cancer
treatment and were not pregnant or less than 8 weeks post partum.
Ethical approval was granted from Ministry of Health in
Burkina Faso (no. 2012-12-089), the Witwatersrand University in
South Africa (no. 110707) and the London School of Hygiene and
Tropical Medicine (no. 7400). All women provided a written
informed consent at the screening visit, and they were given a
reflection period of at least 7 days before enrolment in the study.
A second written informed consent was obtained at the enrolment
visit for enrolment and follow-up over scheduled visits at months
(M) 6, 12 and 18.
careHPV assay. At the M18 visit, endo- and ectocervical sampling
was performed using the careHPV sample collection device
consisting of a careBrush and a vial containing 1ml of careHPV
collection medium (Qiagen). After collection, the brush was stirred
into the collection medium, the cell collection was homogenised by
vortexing and divided into four 0.25-ml aliquots. One aliquot was
maintained at 4 1C until careHPV analysis, performed within less
than 4 weeks, and the others were cryopreserved at  80 1C. The
careHPV test was performed using 50 ml of cervical sample in
collection medium according to the manufacturer’s instruction.
The tests were performed at the respective sites by medical
scientists specifically trained by a Qiagen’s scientist. The positive or
negative result of the careHPV assay was displayed by the careHPV
test controller without additional specification of the luminescent
signal intensity.
HPV detection and genotyping. All cervical specimens were
tested using the INNO-LiPA HPV genotyping Extra assay
(Fujirebio, Les Ulis, France) as previously described (Ngou et al,
2015). This assay, which is based on PCR amplification of HPV
DNA using broad-spectrum SPF10 consensus primers followed by
hybridisation of the amplicons with type-specific oligonucleotides
probes immobilised on membrane strips, allows identification of
28 HPV types, including the 14 HR-HPV types targeted by the
careHPV assay, the possible carcinogenic types HPV26, HPV53,
HPV69, HPV70, HPV73 and HPV82, and the low-risk types
HPV6, HPV11, HPV40, HPV43, HPV44, HPV54, HPV71 and
HPV74. Testing was performed on an aliquot preserved at
 80 1C. A sample was considered HPVþ if at least one of the
type-specific probes or one of the HPV control probes were
detected.
Cytological and histological analysis. An additional cervical
brush was collected from the ecto- and endocervix and rolled on
a glass slide which was fixed with ethanol for cytological reading
using the Papanicolaou method (Pap test). Conventional cytology
was used as liquid-based cytology was not available at that time in
the African laboratories involved in the study. All participants had
visual inspection with acetic acid/Lugol’s iodine (VIA/VILI)
performed by trained nurses and colposcopy performed by trained
colposcopists. Systematic four-quadrant biopsy and directed biopsy
from any suspicious lesions were performed for participants testing
positive by careHPV or who had abnormalities detected on
cytology (XASC-US), VIA/VILI or colposcopy.
The Bethesda system for reporting cervical cytology (Smith,
2002) was used for cytology results and the CIN classification for
histology results. Cytological and histological slides were indepen-
dently examined at each site by two senior pathologists blinded to
the other study results. Pathologists were trained before the start
of the study in order to harmonise slide interpretation between
sites. A quality assessment of over 10% of slides was organised at
6-month intervals by the reference pathology laboratory at
Montpellier University Hospital for both sites, in addition to
existing internal and external quality assurance schemes adhered to
by the National Health Laboratory Service (NHLS) in SA.
The HARP end point committee, composed of five pathologists,
reviewed all histological slides from women with a local diagnosis
of CIN2þ andB10% of slides from women with normal or CIN1
histological findings; the final classification of lesions was based on
a consensus of the committee.
Data analysis. Women included in this analysis comprise all of
the HARP participants who were not lost to follow-up at M18 visit,
including women who may have been treated for CIN2þ detected
at baseline, except if this had been by hysterectomy. Proportions
were compared between groups using w2 or Fisher’s exact test, as
appropriate. Sensitivity, specificity, positive and negative predictive
values (NPV) were calculated with exact binomial 95% confidence
intervals (CI), separately for each country first and then for both
countries combined (sensitivity and specificity only). In addition,
sensitivity and specificity analysis to detect CIN2þ was stratified
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by levels of CD4 T-cell counts (p200 cells per mm3, 201–350 cells
per mm3, 4350 cells per mm3) at entry in the study and at the
time of screening (M18), and by age (o35 and X35 years) and
compared across strata using w2 or Fisher’s exact tests as
appropriate. The comparative analysis of performance of all other
methods and triage combinations for the detection of CIN2þ is
not reported in this paper. Agreement between the careHPV assay
and the INNO-LiPA HPV genotyping Extra assay was assessed
by percentage overall agreement and prevalence-adjusted bias-
adjusted (PABA)-kappa coefficient. All analyses were done using
the Stata version 14 software (Stata Corp, College Station, TX, USA).
RESULTS
A total of 1249 WLHA were enrolled in the study between
November 2011 and October 2012, 625 in BF and 624 in SA. The
analysis was based on the 1052 women (94% overall; BF¼ 492;
SA¼ 560) who had an adequate careHPV result at the M18 visit,
which actually occurred at a median 16 months (interquartile
range (IQR), 15.5–16.8; Figure 1). Among those with valid
careHPV result, 929 (88%; BF¼ 426, SA¼ 503) also had valid
cytology results, and 976 returned for colposcopy (93%; BF¼ 469,
SA¼ 507). Adequate biopsies were taken from 718 (74%) women,
265 (57%) in BF and 453 (89%) in SA. A total of 225 women
(BF¼ 179; SA¼ 46) did not require biopsy as they had no
abnormal cytology, VIA/VILI or colposcopy findings and a
negative careHPV test; they were classified as having ‘normal/
negative’ histology. Thirty three women (BF¼ 25; SA¼ 8) did not
have biopsy taken for reasons such as pregnancy, pain, cervix
atrophy or stenosis. Overall, valid histology results were available
for 943/1052 (90%) women, 444 (90%) in BF and 499 (89%) in SA.
These women had a median (IQR) CD4þ T-cell count of
495 (355–684) cells per mm3, 583 (412–813) cells per mm3 in BF
and 438 (331–571) cells per mm3 in SA. The number of women on
ART was 796 (75%), 400 (81%) in BF and 396 (71%) in SA,
including those who were initiated onto treatment during the study
period.
Overall, 45.1% (474/1052) of women had a positive careHPV
test, 46.5% (229/492) in BF and 43.8% (245/560) in SA (P¼ 0.36).
Any HPV DNA was detected in 83.4% (877/1052) cervical samples,
(80.3% (395/492) in BF and 86.1% (482/560) in SA) by the INNO-
LiPA genotyping Extra assay. When considering only the 14
Women enrolled
n = 1249
(BF = 625; SA = 624)
16 months follow-up
n = 1114
(BF = 550; SA = 564)
careHPV test at follow-up
n = 1072
(BF = 508; SA = 564)
careHPV and LiPA tests
n = 1052
(BF = 492; SA = 560)
Cytology result
n = 929
(BF = 426; SA = 503)
Returned for
colposcopy
n = 976
(BF = 469; SA = 507)
Inadequate/missing
cytology
n = 123
(BF = 66; SA = 57)
Biopsies not
indicated
n = 225
(BF = 179; SA = 46)
Histology results
n = 943
(BF = 444; SA = 499)
Biopsies with
adequate result
n = 718
(BF = 265; SA = 453)
Biopsies not taken
or inadequate
n = 33
(BF = 25; SA = 8)
Figure 1. Study flowchart. BF¼Burkina Faso; SA¼South Africa.
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HR-HPV types targeted by careHPV, 70.0% (736/1052) of samples
(67.9% (334/492) in BF and 71.8% (402/560) in SA) were positive
by genotyping. The overall agreement between the two tests for
HR-HPV DNA detection was 62.4%, with a PABA-kappa value of
0.25 (95% CI: 0.19–0.31) indicating a fair agreement. However,
when analysis was restricted to the 60 women with CIN2þ , the
agreement between tests was 93.3% with a PABA-kappa value of
0.87 (95% CI: 0.74–0.99) indicating an excellent agreement.
Compared with the INNO-LiPA HPV genotyping Extra assay,
analytical sensitivity of careHPV for detecting HR-HPV DNA was
55.4% (95% CI: 51.8–59.1%). The positivity rates of the careHPV
test according to the HR-HPV types detected by genotyping in
single HR-HPV infection cases are presented in Table 1. The
detection rates ranged from 40.0 (HPV56) to 86.4% (HPV58).
Cytology results showed that the overall prevalence of high-
grade squamous intraepithelial lesions (HSIL) was 10.5% (98/929)
with a prevalence of 2.1% (9/426) in BF and of 17.7% (89/503) in
SA. As shown in Table 2, the prevalence of HR-HPV detected by
careHPV or the INNO-LiPA genotyping Extra assay increased with
the lesion grade (Po0.0001), and the sensitivity and specificity
values, combined for both countries, for the detection of HSIL were
88.8% (87/98) and 61.8% (514/831) for careHPV, and 91.8%
(90/98) and 33.7% (280/831), respectively, for INNO-LIPA
genotyping Extra (14 types). The sensitivity of careHPV for
detecting HSIL was lower in SA than in BF (87.6% vs 100%) but
specificity was higher (64.7% vs 56.3%). Negative predictive values
for HSIL were 100% (95% CI: 98.4–100.0) and 96.1% (95% CI:
93.1–98.0) in BF and SA, respectively.
A total of 60 (6.4%) women had high-grade (CIN2þ )
histological lesions, 9 (2.0%) in BF and 51 (10.2%) in SA
(Po0.0001). Overall, the careHPV test was positive in 56/60
(93.3%) women with CIN2þ , 9 (100%) in BF and 47 (92.2%) in
SA, respectively (P40.5). The performance characteristics of the
careHPV and INNO-LiPA genotyping Extra assays for the
diagnosis of CIN2þ in each country and overall are presented
in Table 3. The NPVs of both tests were very similar (98.6–100%),
and when combining the results for the two countries, the
careHPV test was slightly less sensitive (93.3% vs 96.7%) but more
specific (57.9% vs 32.9%) than the INNO-LiPA HPV genotyping
Extra assay. Stratification of results by CD4þ T-cell count showed
that there was no significant difference in sensitivities by CD4þ
T-cell count levels at study entry or contemporary to CIN biopsy at
Table 1. Detection rate of the 14 high-risk HPV types by the
careHPV test among samples with single-type HPV infection
as identified by the INNO-LiPA HPV genotyping Extra assay
INNO-LiPA careHPV
HPV types No. No. %
HPV16 41 19 46.3
HPV18 33 16 48.5
HPV31 49 22 44.9
HPV33 16 10 62.5
HPV35 36 24 66.7
HPV39 21 9 42.9
HPV45 20 16 80.0
HPV51 23 12 52.2
HPV52 83 43 51.8
HPV56 25 10 40.0
HPV58 22 19 86.4
HPV59 3 2 66.7
HPV66 27 15 55.6
HPV68 23 10 43.5
Overall 736 408 55.4
Abbreviation: HPV¼ human papillomavirus.
Table 2. Prevalence of HR-HPV detection by careHPV and INNO-LiPA genotyping Extra assay according to cytological results
Burkina Faso (n¼426) South Africa (n¼503)
Cytology No. careHPV-positive (%) INNO-LiPA-positive (%) No. careHPV-positive (%) INNO-LiPA-positive (%)
No anomalies 368 148 (40.2) 240 (65.2) 14 4 (28.6) 6 (42.9)
Atypical cellsa 16 9 (56.2) 12 (75.0) 84 28 (33.3) 58 (69.0)
LSIL 33 25 (75.8) 28 (84.8) 316 114 (36.1) 215 (68.0)
HSILþ 9 9 (100) 9 (100) 89 78 (87.6) 81 (91.0)
Pb o0.0001 0.0016 o0.0001 0.0011
Abbreviations: BF¼Burkina Faso; HPV¼ human papillomavirus; HSIL¼ high-grade squamous intraepithelial lesions; LSIL¼ low-grade squamous intraepithelial lesions; SA¼ South Africa.
aAtypical squamous cells of undetermined significance (ASC-US), n¼ 13 (BF) and n¼ 52 (SA); Atypical squamous cells, cannot exclude HSIL (ASC-H), n¼ 2 (BF) and n¼ 32 (SA); Atypical
glandular cells (AGC), n¼ 1 (BF).
bTest for trend.
Table 3. Performance of the careHPV and INNO-LiPA assays for the diagnosis of CIN2þ lesions (n¼943)
Burkina Faso (CIN2þ , n¼9) South Africa (CIN2þ , n¼51) Overall (CIN2þ , n¼60)
careHPV INNO-LiPA careHPV INNO-LiPA careHPV INNO-LiPA
Performance indicators
No. of positive tests 206 300 222 358 428 658
No. of CIN2þ positive by test 9 8 47 50 56 58
Sensitivity % 100 (66.4–100) 88.9 (51.7–99.7) 92.2 (81.1–97.8) 98.0 (89.6–99.6) 93.3 (83.8–98.2) 96.7 (88.5–99.6)
Specificity % 54.7 (49.9–59.5) 32.9 (28.5–37.5) 60.9 (56.3–65.5) 31.3 (27.0–35.8) 57.9 (54.5–61.2) 32.0 (29.0–35.2)
PPV % 4.4 (2.0–8.1) 2.7 (1.2–5.2) 21.2 (16.0–27.1) 14.0 (10.6–18.0) –a –
NPV % 100 (98.5–100) 99.3 (96.2–100) 98.6 (96.3–99.6) 99.3 (96.1–100) – –
Abbreviations: CIN¼ cervical intraepithelial neoplasia; HPV¼human papillomavirus.
aPPV (positive predictive value) and NPV (negative predictive value) have not been combined for the two countries as they depend on disease prevalence/incidence which are different for each
country.
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M18. However, specificities decreased with decreasing CD4þ
T-cell counts both at study enrolment (P¼ 0.01) and at M18
(P¼ 0.0008), which corresponded to increasing HR-HPV
prevalences (Table 4). Participants on ART at the time of
enrolment had lower HR-HPV prevalence at M18. careHPV was
slightly more specific in these women (P¼ 0.05). There were no
significant difference by age (Table 4).
DISCUSSION
Considering the high prevalence of HIV infection in sub-Saharan
Africa and the fact that WLHA have an increased risk of development
of cervical precancerous and cancerous lesions, it is important to
target this population in cervical cancer prevention programs. It is
also important to verify that the performance of screening tests is not
modified by HIV serostatus. Several studies conducted in China (Qiao
et al, 2008), India (Labani et al, 2014), Thailand (Trope et al, 2013),
Brazil (Lorenzi et al, 2013) and Nigeria (Gage et al, 2012) on clinician-
or patient-collected cervical samples have shown that cervical
screening based on careHPV testing was a feasible and performant
strategy in low-resource settings. However, none of these studies had
been conducted among WLHA. Thus, the possible impact of HIV
infection on the performance of careHPV for cervical screening
deserved further investigation.
As expected, the positivity rate of careHPV increased with the
grade of cytological lesions, ranging from 87.6 (SA) to 100% (BF)
in women with HSIL. The end point in this study was CIN2þ and
our results indicate that careHPV detected CIN2þ with a high
sensitivity (93.3%) and a high NPV (X99%) in this population of
WLHA. The sensitivity of careHPV for detecting CIN2þ observed
in the present study was very similar to that (94.3%) recently
reported in the only other study among WLHA, although specificity
was not reported in that Ugandan study (Bansil et al, 2015).
The overall specificity of careHPV was relatively low (58%) and
varied by CD4 T-cell strata (between 43 and 62%). A similar
finding, albeit with even lower specificity, was reported in a study
of a similar group of WLHA in Johannesburg tested with HC2
(Firnhaber et al, 2013). The high prevalence of HR-HPV in this
highly exposed population, which increases by level of immune
suppression, may lead to low test specificity, as not all HPV
infections will progress to CIN2þ lesions, or only much later.
Comparison of the careHPV test with the INNO-LiPA HPV
genotyping Extra assay showed that careHPV is less sensitive than the
genotyping assay for the detection of HR-HPV DNA, and that the
rate of detection varies according to the different HR-HPV types.
However, despite the higher analytical sensitivity of the INNO-LiPA
assay for HR-HPV DNA detection, the clinical sensitivity of the two
tests for the diagnosis of CIN2þ was very comparable and the
careHPV test had superior specificity. We may infer that the observed
differences in analytical sensitivity of careHPV may not affect its
usefulness as a screening test. We have previously reported that the
HC2 assay, from which the careHPV test is derived, had an overall
sensitivity and specificity of 88.8% and 55.2%, respectively, to detect
CIN2þ lesions in this study population at their first round of
screening (Ngou et al, 2015), which would make that HPV assay
suitable for screening. The overall sensitivity and specificity of 93.3
and 57.9% observed in the present study indicate that careHPV would
perform equally well for cervical cancer screening of WLHA in sub-
Saharan Africa. Given the relative low specificity of HPV testing, a
triage test such as cytology might be required to determine which
women should be referred to colposcopy. The cost-effectiveness of
this approach should be evaluated.
The high prevalence of HR-HPV infection and CIN2þ
observed in this study are in agreement with data obtained among
similar populations in sub-Saharan Africa (Hawes et al, 2003;
Didelot-Rousseau et al, 2006; Singh et al, 2009; Firnhaber et al,
2010; De Vuyst et al, 2012). Interestingly, while HR-HPV
prevalence as determined by careHPV was not significantly
different between BF and SA, prevalence of cytological and
histological high-grade lesions were markedly higher in SA
compared with BF. A similarly high prevalence of lesions among
HIV-1-infected women in SA has been already reported (Firnhaber
et al, 2013) and factors that may explain the differences observed
between these two countries will be further investigated. At least in
the HARP study, we can rule out issues of histological
misclassification as final histological diagnosis of CIN2þ lesions
was established by a consensus Expert Committee reviewing slides
from both countries simultaneously.
In conclusion, our results indicate that the careHPV test would
be a reliable tool for cervical cancer screening in WLHA. Such a
cost-affordable test should be considered for implementation in
cervical cancer prevention programs in sub-Saharan Africa
targeting women living with HIV/AIDS.
Table 4. Effect of baseline or contemporary CD4 count, age and antiretroviral therapy (ART) on the performance of careHPV
Burkina Faso
n (%)
careHPVþ
South Africa
n (%)
careHPVþ CIN2þ n
Sensitivity %
(95% CI)
P-value
(Fisher’s
Exact)
Specificity %
(95% CI)
P-value
(v2 for
trend/v2)
Baseline CD4 count, cells per mm3
o200 35 (64.1) 23 (50.0) 10 80.0 (44.4–97.5) 45.7 (34.6–57.1)
201–350 49 (48.5) 62 (47.7) 12 100.0 (73.5–100)a 0.2 55.9 (48.6–63.0) 0.01 (for trend)
4350 145 (43.0) 158 (41.5) 37 94.6 (81.8–99.3) 60.2 (56.1–64.1)
Contemporary CD4 count, cells per mm3
o200 20 (69.0) 14 (41.2) 6 100.0 (0.54–100)a 50.9 (36.8–64.9)
201–350 40 (69.0) 68 (56.7) 15 93.3 (68.1–99.8) 40.9 42.6 (34.4–51.0) 0.0008 (for trend)
4350 157 (41.0) 159 (40.2) 38 92.1 (78.6–98.3) 61.8 (57.9–65.5)
Age, years
o35 100 (50.3) 140 (48.8) 36 91.7 (77.5–98.2) 54.8 (49.8–59.8)
X35 129 (44.0) 105 (38.5) 24 95.8 (78.9–99.9) 0.6 60.3 (55.8–64.6) 0.1
ART status
On ART before enrolment 156 (43.9) 147 (40.7) 38 89.5 (75.2–97.1) 60.6 (56.5–64.5)
ART initiated after enrolment 24 (53.3) 17 (48.6) 3 100 (29.2–100)a 0.4 49.3 (37.2–61.4) 0.05
Not on ART 49 (53.3) 81 (49.4) 19 100 (82.4–100)a 52.9 (45.9–59.9)
Abbreviations: CI¼ confidence interval; CIN¼ cervical intraepithelial neoplasia; HPV¼ human papillomavirus.
aOne-sided 97.5% CI.
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